American Association for Cancer Research
15417786mcr140257-sup-131294_1_supp_2517802_n74c55.xlsx (49.79 kB)

Data Supplement from The lncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer

Download (49.79 kB)
posted on 2023-04-03, 17:00 authored by Rohit Malik, Lalit Patel, John R. Prensner, Yang Shi, Matthew K. Iyer, Shruthi Subramaniyan, Alexander Carley, Yashar S. Niknafs, Anirban Sahu, Sumin Han, Teng Ma, Meilan Liu, Irfan A. Asangani, Xiaojun Jing, Xuhong Cao, Saravana M. Dhanasekaran, Dan R. Robinson, Felix Y. Feng, Arul M. Chinnaiyan

Supplementary Table S1. shRNA and primer sequence table.



Long noncoding RNAs (lncRNA) have recently been associated with the development and progression of a variety of human cancers. However, to date, the interplay between known oncogenic or tumor-suppressive events and lncRNAs has not been well described. Here, the novel lncRNA, prostate cancer–associated transcript 29 (PCAT29), is characterized along with its relationship to the androgen receptor. PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. Taken together, these data expose PCAT29 as an androgen-regulated tumor suppressor in prostate cancer.Implications: This study identifies PCAT29 as the first androgen receptor–repressed lncRNA that functions as a tumor suppressor and that its loss may identify a subset of patients at higher risk for disease recurrence.Visual Overview: Mol Cancer Res; 12(8); 1081–7. ©2014 AACR.

Usage metrics

    Molecular Cancer Research



    Ref. manager